Named Bioactive Compounds · Compound
Naringin (Flavanone Glycoside)
Strong Evidenceflavonoid
Hermetica Superfood Encyclopedia
Naringin is a flavanone glycoside primarily found in citrus fruits that supports cardiovascular health by modulating lipid metabolism and reducing arterial stiffness. It works through activation of AMP-activated protein kinase (AMPK) pathways and inhibition of HMG-CoA reductase enzyme activity.
Naringin is a flavanone glycoside naturally abundant in citrus fruits including grapefruit, oranges (Citrus sinensis), bergamot, and tomatoes. It is typically extracted from citrus peels or whole fruit using solvent extraction methods, and occurs in standardized whole-orange extracts used in clinical studies.
Human clinical evidence is limited, with most data from a single-ascending-dose trial (PMID: 31468636) testing 150-900mg naringenin from whole-orange extract in healthy adults, showing peak serum concentrations of 43.11 μM at 4 hours with no serious adverse events. Additional small trials report benefits on lipid profiles and arterial stiffness (PMIDs: 40871686, 39352635), while a phase I trial (NCT01091077) investigated 1g naringenin for HCV inhibition and vLDL reduction.
Clinically studied doses include 150-900mg naringenin (from citrus extracts) as single doses, with 300-900mg achieving therapeutic serum levels. For cardiovascular effects, 600-800 μM/day (approximately 100-130mg naringenin) from standardized citrus extracts has been used in patient populations. Consult a healthcare provider before starting any new supplement.
Naringin (naringenin-7-O-neohesperidoside; C₂₇H₃₂O₁₄; MW 580.53 g/mol) is a flavanone glycoside, not a macronutrient source — it provides negligible calories, protein, fat, or fiber. Its significance is entirely as a bioactive polyphenolic compound. Key profile details: • **Primary bioactive compound**: Naringin itself, typically found at 100–600 mg per liter of grapefruit juice; whole grapefruit peel and albedo contain 2–10% naringin by dry weight. Pomelo peel can contain up to 15–20% by dry weight. • **Aglycone (active metabolite)**: Naringenin (MW 272.26 g/mol), released by intestinal bacterial hydrolysis of the rhamnose-glucose disaccharide (neohesperidose) moiety. Naringenin is the principal absorbed form. • **Bioavailability**: Oral bioavailability of intact naringin is low (~5–8% in animal models). Absorption depends heavily on colonic microflora (e.g., Bacteroides spp.) cleaving the sugar moiety to yield naringenin, which is then absorbed and undergoes extensive phase II hepatic conjugation (glucuronidation and sulfation). Peak plasma concentrations of total naringenin metabolites after 500 mg oral naringin typically reach ~1–6 µmol/L (Tmax ~3–6 hours). Enteric recycling extends the elimination half-life to approximately 2–3 hours for naringenin conjugates. • **Key micronutrient co-occurrence** (when consumed via whole grapefruit): Vitamin C (~38 mg per fruit), potassium (~166 mg per 100 g), folate (~13 µg per 100 g), dietary fiber (~1.6 g per 100 g), and co-occurring flavonoids including hesperidin, narirutin, and furanocoumarins (bergamottin, 6',7'-dihydroxybergamottin — relevant to CYP3A4/CYP1A2 inhibition and drug interactions). • **Other polyphenolic co-constituents in citrus matrix**: Hydroxycinnamic acids (ferulic acid, p-coumaric acid), limonoids (limonin ~5–30 mg/L in juice), and carotenoids (β-cryptoxanthin, lycopene in pink/red grapefruit). • **Supplemental dosing context**: Human clinical trials (e.g., NCT01091077) have used 150–900 mg/day of purified naringin. Commercial supplements typically provide 500 mg per capsule of naringin extract (≥95% purity). • **Solubility and formulation notes**: Naringin has limited water solubility (~1 mg/mL at 25°C), contributing to its poor bioavailability. Naringin complexed with cyclodextrins or delivered as phospholipid complexes (phytosomes) can improve absorption 2–4 fold. Nanoformulations under investigation report up to 6-fold bioavailability enhancement in preclinical models. • **Caloric/macronutrient contribution**: Essentially zero at supplemental doses; when consumed via grapefruit (per 100 g raw): ~42 kcal, 0.77 g protein, 0.14 g fat, 10.7 g carbohydrate, 1.6 g fiber.
Naringin activates AMP-activated protein kinase (AMPK) signaling pathways, which enhances fatty acid oxidation and glucose uptake. It inhibits HMG-CoA reductase enzyme activity, reducing cholesterol synthesis, while also modulating PPAR-γ receptors to improve adiponectin production. Additionally, naringin exhibits antioxidant properties by scavenging reactive oxygen species and upregulating endogenous antioxidant enzymes like superoxide dismutase.
Clinical reviews show moderate evidence for cardiovascular protection in hypercholesterolemic and overweight patients, though sample sizes remain limited. Phase I trial NCT01091077 demonstrated preliminary improvements in lipid profiles, including reduced vLDL cholesterol levels. Limited human trials suggest enhanced arterial stiffness markers and increased adiponectin levels, but larger randomized controlled trials are needed to confirm therapeutic efficacy. Current evidence is promising but requires additional robust clinical validation.
Naringin appears well-tolerated in clinical studies with minimal reported adverse effects at typical supplemental doses. It may interact with cytochrome P450 enzymes, particularly CYP3A4, potentially affecting metabolism of certain medications including statins and blood thinners. Individuals with citrus allergies should exercise caution when using naringin supplements. Safety during pregnancy and lactation has not been established, so use should be avoided during these periods without medical supervision.
